Pembrolizuab Monotherapy Extended Survival in Advanced Lung Cancer
CHICAGO, IL—Patients whose non-small cell lung cancers (NSCLC) expressed more than one per cent of the programmed death ligand-1 (PD-L1) tumor proportion score (TPS) lived longer when treated with the anti programmed death 1 (PD-1) antibody pembrolizumab than a control group of patients receiving platinum-based chemotherapy in the open-label, phase three KEYNOTE-042 study reported at the American Society of Clinical Oncology (ASCO) annual meeting plenary session. https://meetinglibrary.asco.org/record/165950/abstract
Better survival
Principal author of the study, Gilberto Lopes MD, Associate Professor of Clinical Medicine at the University of Miami’s Sylvester Comprehensive Cancer Center tells the Audio Journal of Onclogy patients treated with pebrolizumab monotherapy lived a median of four to eight months longer than those who received chemotherapy and had fewer severe side effects than with chemotherapy (18 per cent as compared with 41 per cent).
John Heymach
You may also like...
Breast cancer chemoprevention: meta-analysis shows SERMs are highly effective 1 May, 2013 
Which patients for bisphosphonate control of breast cancer metastasis? 29 Mar, 2013 
Audio Journal of Oncology Volume 16 Number 8 15 Apr, 2008 - BREAST CANCER: Intraoperative radiotherapy at the time of lumpectomy is as effective as whole breast irradiation and associated with fewer non-cancer deaths 19 Nov, 2013
